Nivalis Therapeutics

March 10, 2016March 16, 2016

Nivalis Expands Clinical Development of Its Cystic Fibrosis CFTR Stabilizer

Cystic Fibrosis, News

Nivalis Therapeutics recently announced the expansion of the clinical development plan for N91115, the company’s investigational, first-in-class stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is defective in ... Read more

January 21, 2016January 25, 2016

Cystic Fibrosis Treatment Granted FDA Orphan Drug Status

Cystic Fibrosis, News

Boulder, Colorado-based Nivalis Therapeutics recently announced the U.S. Food and Drug Administration (FDA) has granted the company’s lead clinical candidate, N91115, Orphan Drug Designation for the treatment of cystic fibrosis (CF). The ... Read more

December 3, 2015December 3, 2015

Cystic Fibrosis Phase 2 Study of CFTR Stabilizer Begins Treatments

Cystic Fibrosis, News

Nivalis Therapeutics, Inc., announced that a Phase 2 clinical study of its lead investigational drug N91115 has begun treating its first patient. Nivalis, a pharmaceutical company focused on cystic fibrosis (CF) treatments, developed N91115 ... Read more

October 8, 2015November 5, 2015

Nivalis Announces Positive Data of Phase 1b Study of Experimental Therapy N91115 in Cystic Fibrosis

Cystic Fibrosis, News

Nivalis Therapeutics, Inc., a pharmaceutical company focused on developing treatments for patients with cystic fibrosis (CF), recently announced positive topline data from its Phase 1b trial assessing N91115, an investigational ... Read more